+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Auranofin Market by Indication, Therapeutic Class, Distribution Channel, End User, Dosage Strength - Global Forecast to 2030- Product Image
Auranofin Market by Indication, Therapeutic Class, Distribution Channel, End User, Dosage Strength - Global Forecast to 2030- Product Image
Sale

Auranofin Market by Indication, Therapeutic Class, Distribution Channel, End User, Dosage Strength - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082722
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Auranofin Market presents evolving opportunities as established therapies adapt to new clinical and commercial realities. Senior executives need a clear view of the shifting regulatory, clinical, and competitive landscape to anticipate challenges and execute on growth strategies.

Market Snapshot: Auranofin Market Growth Perspective

The Auranofin Market grew from USD 218.99 million in 2024 to USD 230.02 million in 2025. It is expected to continue growing at a CAGR of 4.85%, reaching USD 291.00 million by 2030. This growth signals expanding relevance for both new and legacy indications, and highlights the increasing role of established gold compounds within modern treatment paradigms. Future expansion is being shaped by regulatory flexibility, robust clinical pipelines, and dynamic partnerships that respond rapidly to evolving therapeutic and economic needs.

Scope & Segmentation

  • Indication: Oncology (with emphasis on leukemia and lymphoma), Rheumatoid Arthritis (covering moderate and severe cases)
  • Therapeutic Class: DMARDs (including biologics, conventional, and targeted synthetic agents), Gold Compounds
  • Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
  • End User: Home Care Settings, Hospitals, Specialty Clinics
  • Dosage Strength: 3mg, 6mg
  • Region: Americas (United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Market Participants: Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Viatris Inc, Amneal Pharmaceuticals LLC, Fresenius Kabi AG, Aurobindo Pharma Ltd, Dr. Reddy’s Laboratories Ltd, Apotex Inc, Hi-Tech Pharmacal Co., Inc, Sagent Pharmaceuticals Inc

Auranofin Market: Key Takeaways for Decision-Makers

  • Drug repurposing continues to shape development strategies, with Auranofin progressing from its original antirheumatic use toward broader oncology applications driven by targeted drug delivery and molecular imaging advances.
  • Adaptive regulatory processes, including real-world evidence integration and biomarker-guided trial protocols, are making regulatory timelines more predictable and fostering innovation in patient segmentation.
  • Strategic collaborations between established pharmaceutical incumbents, biotechs, and academic partners are enabling resource sharing and risk mitigation, expediting early-stage research and late-phase development.
  • Generics manufacturers are intensifying competition, prompting branded product owners to explore value-added solutions such as digital adherence tools and expanded patient support programs while maintaining market relevance.
  • Regional expansion strategies must account for varied market maturity, regulatory incentives, and access to reimbursement, with tailored approaches proving essential for success across the Americas, EMEA, and Asia-Pacific.
  • Digital and direct-to-patient distribution models are increasing, facilitating greater access while supporting remote disease management and improving patient adherence in outpatient and home settings.

Tariff Impact: Navigating the 2025 Policy Change

The 2025 introduction of new U.S. tariff policies is reshaping global sourcing, manufacturing, and pricing strategies in the Auranofin Market. Pharmaceutical suppliers are adapting by diversifying suppliers, enhancing domestic production, and recalibrating pricing frameworks, seeking to mitigate immediate margin pressures and safeguard long-term supply chain resilience.

Methodology & Data Sources

This analysis applies qualitative and quantitative research, combining structured interviews with clinical and commercial stakeholders and comprehensive review of secondary sources such as peer-reviewed literature, regulatory filings, and proprietary databases. Segmentation and regional patterns are validated using advanced statistical models, with findings peer-reviewed by a council of subject matter experts.

Why This Report Matters

  • Delivers actionable insights to guide commercial, clinical, and investment decisions for senior leaders focusing on opportunity assessment, risk mitigation, and strategic planning.
  • Enables rapid benchmarking of market position by technology, region, and segment, directly supporting go-to-market and innovation strategies.
  • Facilitates resilience planning with timely intelligence on policy impacts, competitive dynamics, and clinical development trends within the Auranofin Market.

Conclusion

Auranofin’s market evolution demonstrates the importance of agility and collaboration in unlocking new therapeutic potential. Decision-makers who proactively engage with these insights will be positioned to navigate complexity and drive sustained growth in an increasingly competitive landscape.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Auranofin Market, by Indication
8.1. Introduction
8.2. Oncology
8.2.1. Leukemia
8.2.2. Lymphoma
8.3. Rheumatoid Arthritis
8.3.1. Moderate
8.3.2. Severe
9. Auranofin Market, by Therapeutic Class
9.1. Introduction
9.2. DMARDS
9.2.1. Biologics
9.2.2. Conventional
9.2.3. Targeted Synthetic
9.3. Gold Compounds
10. Auranofin Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Auranofin Market, by End User
11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals
11.4. Specialty Clinics
12. Auranofin Market, by Dosage Strength
12.1. Introduction
12.2. 3mg
12.3. 6mg
13. Americas Auranofin Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Auranofin Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Auranofin Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Teva Pharmaceutical Industries Ltd
16.3.2. Sandoz International GmbH
16.3.3. Viatris Inc
16.3.4. Amneal Pharmaceuticals LLC
16.3.5. Fresenius Kabi AG
16.3.6. Aurobindo Pharma Ltd
16.3.7. Dr. Reddy’s Laboratories Ltd
16.3.8. Apotex Inc
16.3.9. Hi-Tech Pharmacal Co., Inc
16.3.10. Sagent Pharmaceuticals Inc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. AURANOFIN MARKET MULTI-CURRENCY
FIGURE 2. AURANOFIN MARKET MULTI-LANGUAGE
FIGURE 3. AURANOFIN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL AURANOFIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 16. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. AURANOFIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AURANOFIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AURANOFIN MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AURANOFIN MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AURANOFIN MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AURANOFIN MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AURANOFIN MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AURANOFIN MARKET SIZE, BY TARGETED SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AURANOFIN MARKET SIZE, BY GOLD COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AURANOFIN MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AURANOFIN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL AURANOFIN MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL AURANOFIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL AURANOFIN MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL AURANOFIN MARKET SIZE, BY 3MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL AURANOFIN MARKET SIZE, BY 6MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. CANADA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. CANADA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 53. CANADA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 54. CANADA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 55. CANADA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 56. CANADA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. CANADA AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. CANADA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 59. MEXICO AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. MEXICO AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 61. MEXICO AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. MEXICO AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. MEXICO AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 100. GERMANY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. GERMANY AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 102. GERMANY AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 103. GERMANY AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 104. GERMANY AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 105. GERMANY AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. GERMANY AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. GERMANY AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 108. FRANCE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. FRANCE AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 110. FRANCE AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 111. FRANCE AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 112. FRANCE AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 113. FRANCE AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. FRANCE AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. FRANCE AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 124. ITALY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. ITALY AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 126. ITALY AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 127. ITALY AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 128. ITALY AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 129. ITALY AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ITALY AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. ITALY AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 132. SPAIN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. SPAIN AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 134. SPAIN AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 135. SPAIN AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 136. SPAIN AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 137. SPAIN AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. SPAIN AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SPAIN AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 148. SAUDI ARABIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 156. SOUTH AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 164. DENMARK AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. DENMARK AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 166. DENMARK AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 167. DENMARK AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 168. DENMARK AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 169. DENMARK AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. DENMARK AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. DENMARK AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 180. QATAR AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 181. QATAR AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 182. QATAR AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 183. QATAR AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 184. QATAR AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 185. QATAR AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. QATAR AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. QATAR AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 188. FINLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. FINLAND AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 190. FINLAND AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 191. FINLAND AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 192. FINLAND AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 193. FINLAND AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. FINLAND AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. FINLAND AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 196. SWEDEN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 212. EGYPT AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 213. EGYPT AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 214. EGYPT AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 215. EGYPT AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 216. EGYPT AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 217. EGYPT AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. EGYPT AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. EGYPT AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 220. TURKEY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 221. TURKEY AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 222. TURKEY AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 223. TURKEY AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 225. TURKEY AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. TURKEY AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. TURKEY AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 228. ISRAEL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 229. ISRAEL AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 236. NORWAY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 237. NORWAY AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 238. NORWAY AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 239. NORWAY AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 240. NORWAY AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 241. NORWAY AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. NORWAY AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. NORWAY AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 244. POLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 245. POLAND AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 246. POLAND AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 247. POLAND AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 248. POLAND AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 249. POLAND AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. POLAND AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. POLAND AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 252. SWITZERLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 269. CHINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. CHINA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 271. CHINA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 272. CHINA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 273. CHINA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 274. CHINA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. CHINA AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. CHINA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 277. INDIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 278. INDIA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 279. INDIA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 280. INDIA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 281. INDIA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 282. INDIA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. INDIA AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. INDIA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 285. JAPAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 286. JAPAN AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 287. JAPAN AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 288. JAPAN AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 289. JAPAN AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 290. JAPAN AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. JAPAN AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. JAPAN AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 293. AUSTRALIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 294. AUSTRALIA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 301. SOUTH KOREA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 309. INDONESIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 317. THAILAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 318. THAILAND AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 319. THAILAND AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 320. THAILAND AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 321. THAILAND AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 322. THAILAND AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 323. THAILAND AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 324. THAILAND AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 325. PHILIPPINES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 326. PHILIPPINES AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 327. PHILIPPINES AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 328. PHILIPPINES AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 329. PHILIPPINES AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 330. PHILIPPINES AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 333. MALAYSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 334. MALAYSIA AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 335. MALAYSIA AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 336. MALAYSIA AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 337. MALAYSIA AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 341. SINGAPORE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 342. SINGAPORE AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 343. SINGAPORE AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 344. SINGAPORE AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 345. SINGAPORE AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 346. SINGAPORE AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 347. SINGAPORE AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 348. SINGAPORE AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 349. VIETNAM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 350. VIETNAM AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 351. VIETNAM AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 352. VIETNAM AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 353. VIETNAM AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 354. VIETNAM AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 355. VIETNAM AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 356. VIETNAM AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 357. TAIWAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 358. TAIWAN AURANOFIN MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 359. TAIWAN AURANOFIN MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 360. TAIWAN AURANOFIN MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 361. TAIWAN AURANOFIN MARKET SIZE, BY DMARDS, 2018-2030 (USD MILLION)
TABLE 362. TAIWAN AURANOFIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 363. TAIWAN AURANOFIN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 364. TAIWAN AURANOFIN MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 365. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2024
TABLE 366. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Auranofin market report include:
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Viatris Inc
  • Amneal Pharmaceuticals LLC
  • Fresenius Kabi AG
  • Aurobindo Pharma Ltd
  • Dr. Reddy’s Laboratories Ltd
  • Apotex Inc
  • Hi-Tech Pharmacal Co., Inc
  • Sagent Pharmaceuticals Inc

Table Information

Report AttributeDetails
No. of Pages195
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 230.02 Million
Forecasted Market Value ( USD ) by 2030 $ 291 Million
Compound Annual Growth Rate4.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Auranofin (CAS 34031-32-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Auranofin (CAS 34031-32-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Rheumatology Therapeutics Market by Therapeutic Class, Molecule Type, Indication, Route of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030 - Product Image

Rheumatology Therapeutics Market by Therapeutic Class, Molecule Type, Indication, Route of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • Report
  • 195 Pages
  • Global
From
Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report By Molecule (Pharmaceuticals, Biopharmaceuticals), By Sales Channel (Prescription, OTC), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report By Molecule (Pharmaceuticals, Biopharmaceuticals), By Sales Channel (Prescription, OTC), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Connective Tissue Disease Market Size, Share & Trends Analysis Report By Disease (Rheumatoid Arthritis), By Drug (Pharmaceuticals), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Connective Tissue Disease Market Size, Share & Trends Analysis Report By Disease (Rheumatoid Arthritis), By Drug (Pharmaceuticals), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From

About the Auranofin Market

Auranofin is a drug used to treat immune disorders, such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is an oral gold-based medication that works by suppressing the immune system and reducing inflammation. Auranofin is a relatively new drug, having been approved by the FDA in 1985. It is generally well-tolerated, with few side effects. Auranofin is used in combination with other medications to treat immune disorders. It is often prescribed in combination with non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). Auranofin is also used to treat other conditions, such as lupus and Sjogren's syndrome. The Auranofin market is a growing one, with many companies offering the drug. Some of the companies in the market include Mylan, Teva Pharmaceuticals, and Sandoz. Other companies, such as Pfizer, Merck, and Novartis, also offer Auranofin in some countries. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.